Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p53 expression in colorectal adenomas

L Kaklamanis1, K C Gatter, N Mortensen

  • 1Nuffield Department of Pathology, John Radcliffe Hospital, Oxford, England, United Kingdom.

The American Journal of Pathology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Value of Immunocytochemistry in Differentiating High-Grade: Lymphoma from Other Anaplastic Tumours: A study of anaplastic tumours from 1940 to 1960.

Leukemia & lymphoma·2016
Same author

c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2000
Same author

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.

British journal of cancer·2000
Same author

Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer.

BJU international·2000
Same author

Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen.

Cancer chemotherapy and pharmacology·2000
Same author

Thymidine phosphorylase expression in endometrial carcinomas.

Clinical & experimental metastasis·2000

p53 protein expression abnormalities were found in 26% of benign colorectal adenomas, often in dysplastic areas. This suggests p53 detection may aid in identifying pre-cancerous cells during colorectal cancer screening.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • The p53 tumor suppressor protein plays a critical role in preventing cancer development.
  • Abnormal p53 expression is frequently observed in various cancers, often due to gene mutations.
  • Assessing p53 status in premalignant lesions can provide insights into early neoplastic changes.

Purpose of the Study:

  • To investigate the expression of p53 protein in benign colorectal adenomas.
  • To determine if p53 expression correlates with the presence of dysplasia or concurrent colorectal cancer.
  • To evaluate the utility of p53 immunohistochemistry for detecting pre-malignant cells.

Main Methods:

  • Immunohistochemistry was used to detect p53 protein expression in 72 benign colorectal adenomas.

Related Experiment Videos

  • A panel of monoclonal and polyclonal antibodies against p53 was employed.
  • Adenomas were classified based on patient groups: without (Group I) or with (Group II) concurrent colorectal carcinomas.

    • Main Results:

    • p53 protein was detected in 26% (19/72) of colorectal adenomas.
    • Positive p53 staining was predominantly observed in the most dysplastic areas of the adenomas.
    • p53 expression was also found in 70% (21/30) of concurrent colorectal carcinomas in Group II.

    Conclusions:

    • Abnormal p53 protein expression occurs frequently in colorectal adenomas, likely due to underlying gene mutations.
    • Immunohistochemical detection of p53 may serve as a valuable tool for identifying pre-cancerous cell populations in routine screening.
    • This approach could aid in the early detection and management of colorectal neoplasia.